Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG", "GENE")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease, is pleased to report excellent commercial progress in the USA strategic operations with the following updates:

Strategic Highlights:

• Active engagement with 11 US payer groups with an initial target list of 30 with coverage in tens of millions of lives
• Engagement with 19 US Concierge Medicine Practices with large volume pricing discussions
• Commercial evaluations underway at 10 US medical/family practices
• Re-engagement with 1,600 previous geneType US customers
• Dr Erika Spaeth, a key presenter at the Precision Medicine Leaders...